Literature DB >> 24528025

Time trends of ovarian cancer incidence in China.

Bing Wang1, Shu-Zheng Liu, Rong-Shou Zheng, Fang Zhang, Wan-Qing Chen, Xi-Bin Sun.   

Abstract

The aim of this study was to examine the trend of ovary cancer incidence from 1999 to 2010 in China and predict the burden up to 2020. Crude incidence, age specific incidence and age-adjusted incidence rates were calculated. Joinpoint regression was performed to obtain estimated annual percentages and Bayesian age-period- cohort modeling was used to predict the incidence rate until the year 2020. In China, the crude rate of ovary cancer was 7.91/100,000 and the age-adjusted rate was 5.35/100,000 overall during period 1999-2010. The rates in urban regions were higher than in rural regions. A significant rising trend during 1999-2006 was followed by a drop during 2006-2010 in age-adjusted rates for urban females. In contrast, constant rise was observed in rural women. The decrease in ovary cancer of urban areas tended to be restricted to women aged 50 years and younger. In contrast, increases of ovary cancer in rural areas appeared in virtually all age groups. Although the age-adjusted incidence rate for ovary cancer was predicted to be reduced after year 2011, the crude rate was likely to be relative stable up to 2020. The burden of ovary cancer in China will continue to be relative stable due to the aging population.

Entities:  

Mesh:

Year:  2014        PMID: 24528025     DOI: 10.7314/apjcp.2014.15.1.191

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  20 in total

1.  Microarray expression profiling of long non-coding RNAs in epithelial ovarian cancer.

Authors:  Ye Ding; Da-Zheng Yang; Yong-Ning Zhai; Kai Xue; Feng Xu; Xiao-Yan Gu; Su-Min Wang
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 2.  Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Authors:  Xianwen Hu; Dandan Li; Yujie Fu; Jiashen Zheng; Zelong Feng; Jiong Cai; Pan Wang
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

3.  High levels of KAP1 expression are associated with aggressive clinical features in ovarian cancer.

Authors:  Yanfen Cui; Shaobin Yang; Xin Fu; Jingwen Feng; Shilei Xu; Guoguang Ying
Journal:  Int J Mol Sci       Date:  2014-12-26       Impact factor: 5.923

4.  EphA8 is a prognostic marker for epithelial ovarian cancer.

Authors:  Xiaoqin Liu; Yunzhao Xu; Qin Jin; Wei Wang; Shu Zhang; Xudong Wang; Yuquan Zhang; Xujuan Xu; Jianfei Huang
Journal:  Oncotarget       Date:  2016-04-12

5.  High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer.

Authors:  Ke Wang; Dan Li; Lu Sun
Journal:  Onco Targets Ther       Date:  2016-01-19       Impact factor: 4.147

6.  Ovarian cancer: density equalizing mapping of the global research architecture.

Authors:  Dörthe Brüggmann; Katharina Pulch; Doris Klingelhöfer; Celeste Leigh Pearce; David A Groneberg
Journal:  Int J Health Geogr       Date:  2017-01-13       Impact factor: 3.918

7.  Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.

Authors:  Cong Xu; Hua Li; Miao Yin; Tao Yang; Liguo An; Guiwen Yang
Journal:  Oncotarget       Date:  2017-10-12

8.  Prevalence and its associated psychological variables of symptoms of depression and anxiety among ovarian cancer patients in China: a cross-sectional study.

Authors:  Chun Li Liu; Li Liu; Yi Zhang; Xiao Ze Dai; Hui Wu
Journal:  Health Qual Life Outcomes       Date:  2017-08-17       Impact factor: 3.186

9.  Increase of Incidence and Mortality of Ovarian Cancer during 2003-2012 in Jiangsu Province, China.

Authors:  Zhimei Teng; Renqiang Han; Xingyu Huang; Jinyi Zhou; Jie Yang; Pengfei Luo; Ming Wu
Journal:  Front Public Health       Date:  2016-07-07

10.  Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.

Authors:  Meng Zhou; Yanying Sun; Yifan Sun; Wanying Xu; Zhaoyue Zhang; Hengqiang Zhao; Zhaohua Zhong; Jie Sun
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.